Roche Holding AG’s PD-L1 inhibitor Tecentriq (atezolizumab) is losing one of its US Food and Drug Administration approvals as the Swiss drug maker is withdrawing its indication for first-line metastatic urothelial carcinoma. The move is one of multiple setbacks that PD-1 and PD-L1 checkpoint inhibitors have experienced in that setting and leaves Merck & Co., Inc.’s Keytruda (pembrolizumab) as the major player.
Roche’s Genentech division said 28 November that it would voluntarily withdraw the indication for Tecentriq in adults with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing...
